Simultaneously with the approval of alpelisib + fulvestrant for advanced breast cancer treatment, the US FDA also approved a companion diagnostic test, i.e., therascreen PIK3CA RGQ PCR Kit, for detecting PIK3CA mutation in tissue and/or ctDNA. Here, PIK3CA is linked to breast carcinoma.